Asia
The U.S. SEC continues to tighten the screws on Chinese companies, adding more than 80 companies to its expanding list of companies that might be dropped from U.S. stock exchanges.
Despite a growing product revenue, Beigene reported a net loss of $434.4 million for the first quarter of 2022, as well as updates to its audit from the SEC.
Connect Biopharma Phase II trial on a potential drug for adults with moderate-to-severe ulcerative colitis may have failed to meet its primary endpoint, but the company isn’t giving up yet.
Gongda Xue has been found guilty in a Philadephia courtroom of stealing trade secrets from GlaxoSmithKline. This comes after his sister, Yu Xue, was also convicted for a similar crime.
Hutchmed failed to secure FDA approval for its proposed drug for pancreatic cancer. The company will have to go through another trial if they want U.S. approval.
Chimera’s research comes largely from its GOLD platform, a technology that reprograms RNA gene regulation circuits to alter chimeric antigen receptors (CAR) on T cells.
Global biopharmaceutical companies are pooling their respective resources against difficult-to-treat tumors, CNS diseases and idiopathic pulmonary fibrosis.
The Chinese government has halted the recommendation of Lianhua Qingwen used as a traditional Chinese treatment for mild cases of COVID-19.
The SEC added 12 China companies to their delisting watchlist this week. The companies will need to release evidence by May 3 to remain listed.
Australia’s Chimeric Therapeutics has partnered with WuXi ATU on two autologous CAR T-cell therapies for solid tumors. Switzerland-based CDR-Life closed a $76 million Series A.
PRESS RELEASES